Day traders note CAPR stock price intraday swings are tightening, signaling reduced speculative trading and stronger long-term holder interest. Terms and Privacy Policy Your Privacy Choices CA Privacy Notice More Info Capricor Therapeutics announced it will release its financial results for the second quarter of 2025 on August 13, 2025, after market close, followed by a conference call and webcast with management at 4:30 p.m. ET. The biotechnology company, which focuses on cell and exosome-based therapeutics for rare diseases, highlights its lead candidate, Deramiocel, an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne Muscular Dystrophy (DMD), which has shown promising immunomodulatory effects. Capricor has also entered into a commercialization agreement with Nippon Shinyaku Co., Ltd. for Deramiocel in the U.S. and Japan, pending regulatory approval. The company emphasizes its commitment to developing transformative treatments and provides contact information for media and corporate inquiries. If broken with confirmed volume, projections suggest a test of the $4.60 level within two weeks.